Edition:
United States

Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

50.92USD
1:18pm EDT
Change (% chg)

$-1.10 (-2.11%)
Prev Close
$52.02
Open
$52.18
Day's High
$52.18
Day's Low
$50.72
Volume
372,541
Avg. Vol
794,408
52-wk High
$63.40
52-wk Low
$41.93

Select another date:

Thu, Jul 27 2017

BRIEF-Alkermes qtrly gaap loss per share $0.28

* Qtrly revenues increased 12% year-over-year to $218.8 million

BRIEF-Alkermes announces positive preliminary topline results

* Alkermes announces positive preliminary topline results from phase 3 antipsychotic efficacy study of ALKS 3831 for treatment of schizophrenia

BRIEF-Alkermes announces initiation of study 217 for ALKS 5461

* Alkermes announces initiation of study 217 for ALKS 5461 for treatment of major depressive disorder

BRIEF-Alkermes initiates phase 3 study of ALKS 3831 in young adult patients

* Alkermes announces initiation of phase 3 study of alks 3831 in young adult patients

BRIEF-Alkermes CEO Richard Pops' 2016 total compensation was $9.6 mln vs $12.4 mln in 2015

* CEO Richard Pops' 2016 total compensation was $9.6 million versus $12.4 million in 2015 - sec filing Source text (http://bit.ly/2p9SZ48) Further company coverage:

Select another date: